Cipla Limited (CIPLA.NS)
| Previous close | 882.35 |
| Open | 880.00 |
| Bid | 867.45 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 860.00 - 880.00 |
| 52-week range | 738.10 - 1,005.00 |
| Volume | |
| Avg. volume | 2,301,889 |
| Market cap | 704.507B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 27.06 |
| EPS (TTM) | 32.05 |
| Earnings date | 25 Jan 2022 |
| Forward dividend & yield | 5.00 (0.54%) |
| Ex-dividend date | 09 Aug 2021 |
| 1y target est | 1,064.30 |
- Reuters
Eli Lilly signs deals to boost supply of COVID-19 treatment in India
BENGALURU (Reuters) -Eli Lilly and Co said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients. The agreements will bolster India's arsenal of drugs to battle its catastrophic second wave of the pandemic, which has led to an acute shortage of coronavirus medicines including remdesivir and tocilizumab. The three Indian drugmakers - Cipla Ltd, Lupin Ltd and Sun Pharma - will collaborate with U.S.-based Lilly to help make and sell baricitinib in India.
- Reuters
Cipla doubles remdesivir production to meet 'unprecedented' demand
India's Cipla Ltd has doubled production of COVID-19 medication remdesivir to help meet "unprecedented demand" as the country battles a massive second wave of infections, the drugmaker said on Tuesday. India has overtaken Brazil as the world's second-worst coronavirus-hit country after the United States, having administered about 107 million vaccine doses among a population of 1.4 billion. On Sunday, the country banned the export of anti-viral drug remdesivir and its active pharmaceutical ingredients to deal with crippling shortages of the medication in many parts.
- Reuters
Indian pharma firms go local seeking to end reliance on China
Indian drug companies are looking to local makers of so-called active pharmaceutical ingredients (API) or trying to make them in-house in a bid to end their reliance on China as ties between the two countries soured after a deadly border clash last June. Though India is known as the pharmacy of the world for its massive production capacities of both generic drugs and vaccines, China accounted for half of its API needs in 2019 from nearly nothing three decades ago, industry data shows. Executives at India's Cadila Healthcare, Cipla, Sun Pharmaceutical and Biocon said on Tuesday they were aggressively working on reducing the dependence on the richer rival for raw materials.
